{"id":815501,"date":"2025-02-20T08:04:31","date_gmt":"2025-02-20T13:04:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/"},"modified":"2025-02-20T08:04:31","modified_gmt":"2025-02-20T13:04:31","slug":"incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/","title":{"rendered":"Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><i>Incyte and Genesis will leverage Genesis\u2019 GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets<\/i><\/li>\n<li><i>Incyte receives exclusive rights to develop and commercialize collaboration products<\/i><\/li>\n<\/ul>\n<p>WILMINGTON, Del. &amp; BURLINGAME, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fincyte.com%2F&amp;esheet=54210379&amp;newsitemid=20250220803826&amp;lan=en-US&amp;anchor=Incyte&amp;index=1&amp;md5=dcc8fbedd0eb987251ae8eb0565e61aa\">Incyte<\/a> (Nasdaq:INCY) and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.genesistherapeutics.ai%2F&amp;esheet=54210379&amp;newsitemid=20250220803826&amp;lan=en-US&amp;anchor=Genesis+Therapeutics%2C+Inc.&amp;index=2&amp;md5=5961a51765928739ccc492d6a178bfb9\">Genesis Therapeutics, Inc.<\/a> announced today that the companies have entered into a strategic collaboration focused on the research, discovery and development of novel small molecule medicines, with an initial focus on collaboration targets selected by Incyte.\n<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20250220803826\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250220803826\/en\/<\/a><\/p>\n<p>\nGenesis is pioneering generative and predictive artificial intelligence (AI) technologies to help create therapeutics for challenging targets. Utilizing Genesis\u2019 proprietary AI platform, GEMS (Genesis Exploration of Molecular Space), the partnership will pursue the discovery and optimization of small molecule compounds for the collaboration targets. Incyte is granted exclusive rights for potential clinical development and commercialization of collaboration products.\n<\/p>\n<p>\n\u201cAs a leader in pharmaceutical innovation, Incyte is continually seeking new technologies that can transform how new medicines are discovered and developed,\u201d said Pablo J. Cagnoni, M.D., President and Head of Research and Development at Incyte. \u201cPartnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the discovery of breakthrough small molecules for high-impact targets in our pipeline.\u201d\n<\/p>\n<p>\n\u201cAI has the potential to redefine how we discover small molecule medicines, and our team is at the forefront of this revolution,\u201d said Evan Feinberg, Ph.D., Founder and Chief Executive Officer of Genesis. \u201cWe are pleased to establish this world-class partnership to combine our GEMS AI platform with Incyte\u2019s deep expertise and track record in drug discovery and development, with the shared goal of advancing critical treatments for patients with severe diseases.\u201d\n<\/p>\n<p><b>Terms of the Agreement<\/b><\/p>\n<p>\nUnder the terms of the agreement, Genesis will receive an upfront payment of $30 million. Genesis and Incyte have agreed to collaborate on two initial targets, and Incyte will have the option to nominate an additional target for a predetermined fee. If all milestones are achieved, Genesis is eligible to receive up to $295 million in development, regulatory and commercial milestone payments per target. Genesis is also eligible to receive tiered royalties on sales of any collaboration products, once approved.\n<\/p>\n<p><b>About Genesis Therapeutics<\/b><\/p>\n<p>\nGenesis Therapeutics, Inc. is an AI-focused biotechnology company leveraging its generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space), for small molecule drug discovery. GEMS integrates proprietary AI methods, including language models, diffusion models and physical simulation, to generate and optimize molecules for complex targets. Genesis has raised over $300 million from leading life science, tech, and AI-focused investors, and is building a therapeutics pipeline for a variety of high-impact targets. Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. For more information on Genesis, please visit the company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.genesistherapeutics.ai&amp;esheet=54210379&amp;newsitemid=20250220803826&amp;lan=en-US&amp;anchor=www.genesistherapeutics.ai&amp;index=3&amp;md5=2a5c877c8cc62af95acabf8dd958517a\">www.genesistherapeutics.ai<\/a>.\n<\/p>\n<p><b>About Incyte<\/b><\/p>\n<p>\nA global biopharmaceutical company on a mission to <i>Solve On.<\/i>, Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation &amp; Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.\n<\/p>\n<p>\nFor additional information on Incyte, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.incyte.com%2F&amp;esheet=54210379&amp;newsitemid=20250220803826&amp;lan=en-US&amp;anchor=Incyte.com&amp;index=4&amp;md5=1542a90232e3c445f4f858ed6960941b\">Incyte.com<\/a> or follow us on social media: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fincyte%2F&amp;esheet=54210379&amp;newsitemid=20250220803826&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=5fb6aff0eccc7eed254ce08d905b03a7\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FIncyte&amp;esheet=54210379&amp;newsitemid=20250220803826&amp;lan=en-US&amp;anchor=X&amp;index=6&amp;md5=8917ebcfa698f1026f0db8dbf9cc72d7\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fincyte%2F&amp;esheet=54210379&amp;newsitemid=20250220803826&amp;lan=en-US&amp;anchor=Instagram&amp;index=7&amp;md5=d0fa5bb16c56000faf85903c3745afe8\">Instagram<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FIncyte%2F&amp;esheet=54210379&amp;newsitemid=20250220803826&amp;lan=en-US&amp;anchor=Facebook&amp;index=8&amp;md5=527da6429a81fdfc7becb20d4f6d2d3c\">Facebook<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FUCQu_9fYXOTWn4q3h-c0sKCg&amp;esheet=54210379&amp;newsitemid=20250220803826&amp;lan=en-US&amp;anchor=YouTube&amp;index=9&amp;md5=d4d638221f6bbf75754dade1ee8b6303\">YouTube<\/a>.\n<\/p>\n<p><b>Incyte Forward-Looking Statements<\/b><\/p>\n<p>\nExcept for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential of the products arising from the collaboration with Genesis Therapeutics, contain predictions, estimates and other forward-looking statements.\n<\/p>\n<p>\nThese forward-looking statements are based on Incyte\u2018s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by regulatory authorities; Incyte\u2018s dependence on its relationships with its collaboration partners; the efficacy or safety of Incyte\u2018s products and the products of Incyte\u2018s collaboration partners; the acceptance of Incyte\u2018s products and the products of Incyte\u2018s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte\u2018s reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended December 31, 2024. Incyte disclaims any intent or obligation to update these forward-looking statements.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220803826r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250220803826\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250220803826\/en\/<\/a><\/span><\/p>\n<p><b>Genesis Media Contact:<br \/>\n<\/b><br \/>Thermal for Genesis<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:press@genesistherapeutics.ai\">press@genesistherapeutics.ai<\/a><\/p>\n<p><b>Incyte Contacts:<\/b><\/p>\n<p><b>Media<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:media@incyte.com\">media@incyte.com<\/a><\/p>\n<p><b>Investors<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:ir@incyte.com\">ir@incyte.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California Delaware<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Technology Research Health Technology Biotechnology Health Pharmaceutical Science Artificial Intelligence Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250220803826\/en\/2387137\/3\/Incyte_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250220803826\/en\/2387139\/3\/Genesis_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration Incyte and Genesis will leverage Genesis\u2019 GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets Incyte receives exclusive rights to develop and commercialize collaboration products WILMINGTON, Del. &amp; BURLINGAME, Calif.&#8211;(BUSINESS WIRE)&#8211;Incyte (Nasdaq:INCY) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration focused on the research, discovery and development of novel small molecule medicines, with an initial focus on collaboration targets selected by Incyte. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20250220803826\/en\/ Genesis is pioneering generative and predictive artificial intelligence (AI) technologies to help create therapeutics for challenging targets. Utilizing Genesis\u2019 proprietary AI platform, GEMS &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-815501","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration Incyte and Genesis will leverage Genesis\u2019 GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets Incyte receives exclusive rights to develop and commercialize collaboration products WILMINGTON, Del. &amp; BURLINGAME, Calif.&#8211;(BUSINESS WIRE)&#8211;Incyte (Nasdaq:INCY) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration focused on the research, discovery and development of novel small molecule medicines, with an initial focus on collaboration targets selected by Incyte. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20250220803826\/en\/ Genesis is pioneering generative and predictive artificial intelligence (AI) technologies to help create therapeutics for challenging targets. Utilizing Genesis\u2019 proprietary AI platform, GEMS &hellip; Continue reading &quot;Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-20T13:04:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220803826r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration\",\"datePublished\":\"2025-02-20T13:04:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\\\/\"},\"wordCount\":855,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250220803826r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\\\/\",\"name\":\"Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250220803826r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-02-20T13:04:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250220803826r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250220803826r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/","og_locale":"en_US","og_type":"article","og_title":"Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration - Market Newsdesk","og_description":"Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration Incyte and Genesis will leverage Genesis\u2019 GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets Incyte receives exclusive rights to develop and commercialize collaboration products WILMINGTON, Del. &amp; BURLINGAME, Calif.&#8211;(BUSINESS WIRE)&#8211;Incyte (Nasdaq:INCY) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration focused on the research, discovery and development of novel small molecule medicines, with an initial focus on collaboration targets selected by Incyte. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20250220803826\/en\/ Genesis is pioneering generative and predictive artificial intelligence (AI) technologies to help create therapeutics for challenging targets. Utilizing Genesis\u2019 proprietary AI platform, GEMS &hellip; Continue reading \"Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-20T13:04:31+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220803826r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration","datePublished":"2025-02-20T13:04:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/"},"wordCount":855,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220803826r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/","name":"Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220803826r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-02-20T13:04:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220803826r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220803826r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-therapeutics-announce-strategic-ai-focused-research-collaboration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=815501"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815501\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=815501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=815501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=815501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}